Uncategorized

VIDEO: Aerie updates Rhopressa, Rocklatan programs

by Healio ophthalmology • 2020/02/18 • 0 Comments

SAN FRANCISCO — At Glaucoma 360: New Horizons Forum, Thomas A. Mitro, president and chief operating officer of Aerie Pharmaceuticals, updates the company’s progress with Rhopressa (netarsudil ophthalmic solution 0.02%) and Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution), and discusses receiving the Glaucoma Research Foundation’s Catalyst Award.

Full Story →

← Lineage Cell Therapeutics to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2020)

Be My Eyes Raises $2.8M in Funding for Platform to Support Blind and Visually Impaired Worldwide →

Post navigation